Drug Utilization Review (DUR) Meeting Minutes

June 7, 2017

Members Present: Tanya Schmidt, Laura Schield, Jeffrey Hostetter, Michael Quast, Gaylord Kavlie, Katie Kram, Wendy Brown, Zach Marty, LeNeika Roehrich, Andrea Honeyman, Carlotta McCleary,

Members Absent: Michael Booth, Peter Woodrow

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy, Gary Betting

Old Business

Chair W. Brown called the meeting to order at 1:00 p.m. Chair W. Brown asked for a motion to approve the minutes of the March meeting. G. Kavlie moved that the minutes be approved and K. Kram seconded the motion. Chair W. Brown called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Review Top 15 Therapeutic Categories/Top 25 Drugs

B. Joyce presented the quarterly review of the top 15 therapeutic classes by total cost of claims, top 25 drugs based on number of claims, and top 25 drugs based on claims cost for the 1st quarter of 2017.

PDL Update

A. Murphy gave an update on drugs that have been added to prior authorization. Adenovate 3000 unit and Ixinity were added to the antihemophilia criteria. Airduo Respiclick and fluticasone/salmeterol were added to the steroid Beta2 agonist criteria. Xultophy was added to the GLP-1 criteria. Trulance was added to the IBS/Constipation criteria. Synjardy was added to the SGTL2 Inhibitors criteria. Siliq was added to the cytokine modulators criteria. Migergot was added to the DHE criteria. Arymo ER was added to the cytokine modulators criteria. Austedo, Dupixent, Emflaza, Esbriet, Ingrezza, and Ocaliva were added to the medications >$3,000 criteria. Defitelio, Lemtrada, Lucentis, Ocrevus, Quadramet, and Tysarbi were added to the Medical Billing Only list of medications. Xenical was removed from the list of covered medications by North Dakota Medicaid.

New Business

Proglycem

T. DeRuiter and B. Joyce reviewed Proglycem with the Board. A motion was made by J. Hostetter to manage the class through prior authorization. The motion was seconded by G. Kavlie. This topic will be reviewed at the next meeting.
Biltricide

T. DeRuiter and B. Joyce reviewed Biltricide with the Board. A motion was made by J. Hostetter to manage the class through prior authorization. The motion was seconded by G. Kavlie. This topic will be reviewed at the next meeting.

Physician Prescribing Patterns for Select Therapeutic Categories

B. Joyce presented data showing the top prescriber utilization of select medications in therapeutic drug classes as well as the top prescribers with patients on multiple medications within the selected classes of medications, in order to evaluate utilization trends and potential outliers. Therapeutic classes evaluated included antidepressants, antipsychotics, and stimulants for ADHD. Prescriber utilization was presented both in terms of number of prescriptions for and/or patients on select medications in the first quarter and in terms of percent utilization of selected medications within their therapeutic class in the first quarter. The board discussed the value and limitations of the data, as well as potential drug classes and topics to present at future DUR board meetings.

Review of Antidepressant Non-compliance

B. Joyce presented data demonstrating antidepressant underutilization before and after an educational RDUR intervention letter was sent to prescribers, which showed a significant reduction in underutilization after letters were sent. This topic will continue to be evaluated with interventions sent in future RDUR review cycles.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. G. Kavlie moved to approve the new criteria and Z. Marty seconded the motion. W. Brown called for a voice vote. The motion passed with no audible dissent.

The next DUR Board meeting will be held September 6, 2017 at the Capitol in the Brynhild Haugland room in Bismarck. W. Brown adjourned the meeting.